Pfizer will purchase biotech firm Medivation, which specializes in cancer treatments, for some $14 billion, the US pharma giant said in a statement on Monday. Pfizer's offer for the San Francisco-based Medivation goes far beyond the company's market value of $11.1 billion. The boards of directors of both companies have unanimously approved the merger, the statement said. "The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer," said Ian Read, Pfizer chairman and chief executive officer. |
|
GMT 21:55 2018 Tuesday ,23 January
Trump to meet May, Netanyahu, Kagame in Davos: White HouseGMT 21:53 2018 Tuesday ,23 January
S&P 500, Nasdaq end at records as technology shares gainGMT 21:51 2018 Tuesday ,23 January
Venezuela's Maduro says ready to run for second termGMT 21:49 2018 Tuesday ,23 January
Trump to tell Erdogan of concern over Syria offensiveGMT 21:47 2018 Tuesday ,23 January
Trump says NAFTA talks are 'moving along pretty well'GMT 22:13 2018 Monday ,22 January
Senate votes to end US shutdown, bill heads to HouseGMT 22:12 2018 Monday ,22 January
Dow, S&P, Nasdaq finish at records as US goverment shutdown endsGMT 22:10 2018 Monday ,22 January
Turkish soldier killed in Syria operationMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2023 ©